The study emphasizes the importance of vigilant monitoring and personalized thromboprophylaxis to prevent COVID-19-related thromboembolism in cancer patients.
Cancer patients undergoing anti-cancer treatments and who are admitted to the hospital due to COVID-19, may face an elevated likelihood of experiencing venous thromboembolisms (VTE), which are potentially severe blood clots within the veins, revealed study published in the JAMA Oncology (1✔ ✔Trusted Source
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
Go to source).
Potential Cancer Drug Links to Venous Thromboembolisms
The drugs, however, were not tied to a higher risk of arterial thromboembolism, said the researchers from the universities of California, Cincinnati, Texas. For the study, the team from across the US analysed data on 4,988 cancer patients worldwide who had lab-confirmed SARS-CoV-2 infection from March 2020 to December 2021. They compared the 1,869 patients who had received systemic anti-cancer therapies such as endocrine therapy, immunomodulators, and chemotherapy in the 3 months before COVID-19 with those who hadn't.‘Individuals undergoing systemic anti-cancer treatment experienced a 33 percent elevated relative risk of venous thromboembolisms (VTE). #BloodClots #COVID-19 #CancerPatients ’
They also discovered that patients with thromboembolic events (TEEs) had high intensive care unit admission (46 percent) and mechanical ventilation (31 percent) rates. The risk of death in patients with TEEs was associated with poor physical abilities and active or progressing cancer. Reference:
- Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19 - (https://jamanetwork.com/journals/jamaoncology/fullarticle/2808502)